The KPV peptide is made of just three amino acids (lysine, proline and valine) taken from the end of alpha-melanocyte-stimulating hormone (alpha-MSH). It keeps that hormone’s anti-inflammatory effects without its skin-darkening effect.[1] Taken by mouth, it reduced colitis in mice.[2] FDA found no clinical studies of KPV in people, and it is not FDA-approved.[5]

This profile covers what KPV is, how it works, what the 2008 Emory University mouse study (Dalmasso and colleagues, Gastroenterology) and other animal studies found for gut inflammation,[2][3] oral capsules vs injection, side effects, dosage and its regulatory status.

What is KPV?

Alpha-MSH is a hormone best known for triggering skin pigmentation, but it also calms inflammation. Researchers found that its last three amino acids, KPV (positions 11 to 13), keep much of the anti-inflammatory activity on their own.[1] KPV is sold as capsules and injections, and as part of the KLOW peptide blend.

How KPV works

In gut cells, KPV is carried inside by PepT1, a transporter that normally absorbs small protein fragments from food. Once inside, nanomolar amounts of KPV blocked NF-kB and MAPK, two major inflammation pathways.[2] Some of its effects may also work through the melanocortin receptors that alpha-MSH acts on.[1][3]

Not everyone agrees on that last point. In its 2026 review, FDA wrote that KPV does not appear to act on the melanocortin receptors, that it lacks alpha-MSH’s tanning activity, and that its exact molecular targets are unknown.[5] The German colitis study likewise concluded that KPV’s effects seem to be at least partly independent of the MC1 receptor.[3]

KPV benefits: what the research shows

All published evidence comes from mice and cell studies:

  • Colitis: KPV given in drinking water reduced chemically induced colitis in mice.[2]

  • Severe colitis: a German group found KPV sped recovery and reduced inflammation markers; in mice lacking a working melanocortin receptor, it prevented all deaths in the treated group.[3]

  • Targeted delivery: researchers packed KPV into nanoparticles that home to inflamed colon tissue; taken by mouth, they eased ulcerative colitis in mice.[4]

  • Newer lab work (Korea): KPV reduced fat accumulation in fat cells and limited weight gain in mice on a high-fat diet[13], and protected skin cells from damage caused by fine dust pollution[14].

A closer look at the key mouse studies

Emory University, 2008 (Dalmasso and colleagues). The team first tested KPV on human gut lining cells and human immune T cells in the lab, then gave it to mice in their drinking water. They used two standard chemical colitis models, DSS and TNBS. Oral KPV lowered the rate of colitis and reduced inflammatory signaling molecules in the colon. The authors concluded KPV “might be” a new treatment for inflammatory bowel disease (IBD), which is a hypothesis, not a result in people.[2]

University of Münster, 2008 (Kannengiesser and colleagues). In DSS colitis, KPV-treated mice recovered earlier, regained more body weight and had fewer inflammatory cells in the colon lining. KPV also helped in a second model, T-cell transfer colitis.[3]

Targeted nanoparticles, 2017. Researchers coated tiny particles (about 272 nanometers across) with hyaluronic acid so they would stick to inflamed colon cells, then wrapped them in a gel taken by mouth. This version protected the colon lining better than KPV particles without the coating.[4]

None of these studies used the capsules or injections sold online, and mice handle drugs differently from people.

KPV capsules vs injection

Because the gut transporter PepT1 absorbs KPV, the strongest animal evidence is for oral use, which is why capsules are popular.[2] No study has tested injected KPV for gut inflammation, or compared capsules with injections.

For skin, FDA reports that in a lab test on human skin, KPV did not pass through the skin well, which limits creams.[5] That matters because the compounding nomination FDA reviewed in 2026 was for a 0.1% cream or gel for wound healing and inflammatory skin conditions such as psoriasis and eczema. FDA noted that poor skin penetration might lower the risk of whole-body effects, but could also keep KPV from reaching the deeper skin layers where it would need to work.[5]

KPV side effects and safety

  • No human data: FDA found no clinical studies and no adverse event reports.[5]
  • No toxicity studies: FDA identified no animal toxicity studies of KPV.[5]
  • Product quality: for injectable peptides like KPV, FDA’s main concerns are immune reactions to impurities or clumped peptide.[9]
  • Unregulated products: a 2026 review warns that research-chemical peptides carry risks of contamination and dosing errors.[12]
  • Unclear identity: FDA found that KPV is sold under one common name for different forms (the free base and an acetate salt), with no official drug standard, and that available certificates of analysis lacked impurity, clumping and microbial testing.[5]

FDA also points out that no adverse event reports does not mean a substance is safe: reporting is voluntary, and problems with compounded or unregulated products often go unreported.[5]

Who should talk to a clinician first

Anyone with Crohn’s disease or ulcerative colitis should not swap prescribed treatment for KPV. In its KPV review, FDA noted that approved therapies with established benefit already exist for wounds and for many inflammatory diseases, including psoriasis and eczema.[5] Because there are no human safety data at all, people who are pregnant or breastfeeding, have a weakened immune system, or take several medicines have no information to go on.[5]

Useful questions to ask a doctor include: Is my gut or skin condition well controlled on approved treatment? Could a product bought online interact with my medicines? What symptoms would mean I should stop and get checked?

KPV dosage: what has been studied

No dose of KPV has been studied in people.[5] In mice, KPV was given in drinking water or as oral nanoparticles, at doses that cannot be directly converted to humans.[2][4] For converting a vial’s milligrams into syringe units, see our peptide calculator.

  • Not FDA-approved. KPV is not part of any approved drug.[5]
  • 2023: FDA listed KPV among substances that may pose significant safety risks in compounding.[9]
  • April 2026: after the nomination was withdrawn, FDA removed KPV from that list, which is not an approval.[9][10]
  • July 2026: FDA’s compounding advisory committee reviewed KPV for wound healing and inflammatory conditions.[7] FDA recommended against it, but the committee voted 8 to 6, with one abstention, in favor.[6][8] The vote is not binding, and no rule had followed as of our last review.
  • Sport: KPV is not named on WADA’s 2026 Prohibited List.[11]

This is general information, not legal advice.

KPV in the KLOW blend

KPV is the ingredient that turns the GLOW blend into KLOW. Its gut-focused animal evidence differs from the skin and tissue-repair claims made for the other ingredients, BPC-157, TB-500 and GHK-Cu.